Patients were scheduled for quarterly site visits
during the trial. All investigators were encouraged
to treat all the patients according to local guide-
lines to achieve the most effective glycemic control
(Table S3 in the Supplementary Appendix), and
additional noninvestigational antihyperglycemic
medication (nonincretin-based therapy) could be
added or adjusted.